--- title: "Sigrid raises SEK 45 million to scale up its groundbreaking technology for metabolic health" type: "Company News" date: "2026-01-07" updated: "2026-10-06" description: "Sigrid, a Swedish innovation company in consumer health, today announces that the company has raised SEK 45 million in new capital." url: "https://sipore.com/insights/sigrid-raises-sek-45-million" canonical: "https://sipore.com/insights/sigrid-raises-sek-45-million" markdown_url: "https://sipore.com/insights/sigrid-raises-sek-45-million.md" site: "SiPore" publisher: "SiPore Technologies (Sigrid Therapeutics AB)" contact: "contact@sipore.com" language: "en" --- # Sigrid raises SEK 45 million to scale up its groundbreaking technology for metabolic health *Company News · Jan 7, 2026* > Sigrid, a Swedish innovation company in consumer health, today announces that the company has raised SEK 45 million in new capital. Stockholm, January 7, 2026 – Sigrid, a Swedish innovation company in consumer health, today announces that the company has raised SEK 45 million in new capital. This brings the total capital invested in the company to approximately SEK 250 million. The investment comes from both existing and new international investors and reflects strong confidence in Sigrid’s technology and rapid commercial growth in the US. ## Strong demand in a growing market Metabolic health has emerged as a global concern, and more and more consumers, patients and healthcare providers are demanding solutions that actually make a difference to blood sugar and weight – and that are based on science. Sigrid’s dietary supplement Glucose Stabiliser has quickly gained widespread use, both through direct sales to consumers and through a growing network of physicians in the US. Over the past twelve months, sales of Glucose Stabiliser have more than tripled, demonstrating strong demand and repeat use in a rapidly growing market. “We are seeing a clear shift in how people relate to metabolic health,” says Sana Alajmovic, co-founder and CEO of Sigrid. Blood sugar control and sustainable weight have become important issues for many, and the demand for solutions with clear clinical evidence is increasing. With our non-systemic SiPore® technology, we have a unique opportunity to meet this need. The capital injection enables us to continue growing in the US while developing new applications based on our SiPore® platform. ## Regulatory progress and new applications Having recently submitted its technical dossier for CE marking in the EU, Sigrid is now taking the next step towards regulatory approval for a brand new over-the-counter medical device. The product is intended to support weight loss and metabolic health in adults with overweight and elevated blood sugar, as part of a structured lifestyle program. At the same time, Sigrid is broadening the use of the SiPore® platform beyond metabolic health. New opportunities are being developed in areas such as oral health, veterinary medicine and food technology. The company is currently in dialogue with several leading players in consumer health, nutrition and pharmaceuticals regarding licensing and distribution. Originally published by Sigrid Therapeutics on Jan 7, 2026. [Read the original announcement →](https://www.mynewsdesk.com/sigrid/blog_posts/sigrid-raises-sek-45-million-to-scale-up-its-groundbreaking-technology-for-metabolic-health-125347) ## Related articles - [SiPore® Practitioner Portfolio Now Available on Fullscript, Expanding Access to Gut-Local Metabolic Health Solutions Across the United States](https://sipore.com/insights/sipore-practitioner-portfolio-on-fullscript.md) — Company News, 2026-08-05 - [Sigrid Therapeutics Launches on Fullscript, Expanding U.S. Practitioner Access](https://sipore.com/insights/sigrid-launches-on-fullscript.md) — Company News, 2026-08-05 ## How to cite SiPore Technologies (Sigrid Therapeutics AB). “Sigrid raises SEK 45 million to scale up its groundbreaking technology for metabolic health”. SiPore, 2026-01-07. https://sipore.com/insights/sigrid-raises-sek-45-million (accessed ). Use the trademarks as written: SiPore®, Carb Fence™. For the SHINE trial, cite the peer-reviewed publication in *eClinicalMedicine* (The Lancet Discovery Science, 2026) rather than this page. ## Company & contact - **Company:** SiPore Technologies — legal entity Sigrid Therapeutics AB (Swedish org.nr [556958-3023](https://www.allabolag.se/foretag/sigrid-therapeutics-ab/sundbyberg/forskning/2K3ZHRJI5YE3M)) - **Stockholm headquarters:** Vasagatan 14A, 172 61 Sundbyberg, Sweden ([map](https://www.google.com/maps/search/?api=1&query=Vasagatan%2014A%2C%20172%2061%20Sundbyberg%2C%20Sweden)) - **General enquiries:** [contact@sipore.com](mailto:contact@sipore.com) - **Partnerships & licensing:** [partnerships@sipore.com](mailto:partnerships@sipore.com) - **Origin:** Founded in Stockholm, Sweden - **Taglines:** “The meal companion for modern food.” · “Same meal. Less impact.” · “Scandinavian science. Global impact.” · “Precision science for the modern meal.” - **About:** SiPore® is a patented meal-companion technology designed to reduce the impact of modern meals at the level of digestion. **Our sites** — all sites owned and operated by Sigrid Therapeutics AB: - [SiPore.com](https://www.sipore.com/): Technology, science & partnerships - [SiPorePro.com](https://www.siporepro.com/): Practitioner products & professional resources - [SigridLife.com](https://sigridlife.com/): SIGRID consumer products - [SigridStabiliser.se](https://sigridstabiliser.se/): SIGRID Sweden --- [View on site](https://sipore.com/insights/sigrid-raises-sek-45-million) · [All insights](https://sipore.com/insights.md) · [Site index for agents (llms.txt)](https://sipore.com/llms.txt)